11 results on '"A. Goldkuhle"'
Search Results
2. First-line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta-analysis
- Author
-
Aldin, Angela, additional, Besiroglu, Burcu, additional, Adams, Anne, additional, Monsef, Ina, additional, Piechotta, Vanessa, additional, Tomlinson, Eve, additional, Hornbach, Carolin, additional, Dressen, Nadine, additional, Goldkuhle, Marius, additional, Maisch, Philipp, additional, Dahm, Philipp, additional, Heidenreich, Axel, additional, and Skoetz, Nicole, additional
- Published
- 2023
- Full Text
- View/download PDF
3. First-line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta-analysis
- Author
-
Angela Aldin, Burcu Besiroglu, Anne Adams, Ina Monsef, Vanessa Piechotta, Eve Tomlinson, Carolin Hornbach, Nadine Dressen, Marius Goldkuhle, Philipp Maisch, Philipp Dahm, Axel Heidenreich, and Nicole Skoetz
- Subjects
Pharmacology (medical) - Published
- 2023
4. Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma
- Author
-
Peter Borchmann, Nicole Skoetz, Marius Goldkuhle, Ina Monsef, Annika Oeser, Mohamed A. Abd El Aziz, Julia Caro-Valenzuela, Moritz Ernst, Burcu Besiroglu, and Lise J Estcourt
- Subjects
medicine.medical_specialty ,Receptors, Chimeric Antigen ,Blinding ,business.industry ,Visual analogue scale ,Clinical study design ,Cell- and Tissue-Based Therapy ,Immunotherapy, Adoptive ,Transplantation ,Clinical trial ,Observational Studies as Topic ,Quality of life ,Internal medicine ,Humans ,Medicine ,Pharmacology (medical) ,Observational study ,Lymphoma, Large B-Cell, Diffuse ,Neoplasm Recurrence, Local ,business ,Adverse effect - Abstract
Background Diffuse large B‐cell lymphoma (DLBCL) is an aggressive cancer of the lymphatic system. About 30% to 40% of people with DLBCL experience relapse and 10% are refractory to first‐line treatment usually consisting of R‐CHOP chemotherapy. Of those eligible for second‐line treatment, commonly consisting of salvage chemotherapy followed by autologous stem‐cell transplantation (ASCT), around 50% experience relapse. With a median overall survival of less than six to 12 months, the prognosis of individuals who relapse or are refractory (r/r) to advanced lines of treatment or of those who are ineligible for ASCT, is very poor. With the introduction of chimeric antigen receptor (CAR) T‐cell therapy, a novel treatment option for these people is available. Objectives To assess the benefits and harms of chimeric antigen receptor (CAR) T‐cell therapy for people with relapsed or refractory (r/r) DLBCL. Search methods An experienced information specialist performed a systematic database search for relevant articles on CENTRAL, MEDLINE and Embase until September 11th, 2020. We also searched trial registries and reference lists of identified studies up to this date. All search results were screened by two authors independently and a third author was involved in case of discrepancies. Selection criteria We included prospectively planned trials evaluating CAR T‐cell therapy for people with r/r DLBCL. We had planned to include randomised controlled trials (RCTs) and we flexibly adapted eligibility criteria to the most reliable study designs available. We excluded studies involving fewer than 10 participants with r/r DLBCL and studies with a proportion of participants with r/r DLBCL below 70%, unless data were reported separately for this subgroup. Data collection and analysis Two review authors extracted data and performed risk of bias ratings independently. A third author was involved in case of disagreements. As our search did not yield any completed RCTs, prospective controlled non‐randomised studies of interventions (NRSIs) or prospective observational studies with a control group, we did not meta‐analyse data and reported all results narratively. We adopted the GRADE approach to assess the certainty of the evidence for prioritised outcomes. Main results We identified 13 eligible uncontrolled studies evaluating a single or multiple arms of CAR T‐cell therapies. We also identified 38 ongoing studies, including three RCTs. Ten studies are awaiting classification due to completion with no retrievable results data or insufficient data to justify inclusion. The mean number of participants enrolled, treated with CAR T‐cell therapy and evaluated in the included studies were 79 (range 12 to 344; data unavailable for two studies), 61 (range 12 to 294; data unavailable for one study) and 52 (range 11 to 256), respectively. Most studies included people with r/r DLBCL among people with other haematological B‐cell malignancies. Participants had received at least a median of three prior treatment lines (data unavailable for four studies), 5% to 50% had undergone ASCT (data unavailable for five studies) and, except for two studies, 3% to 18% had undergone allogenic stem‐cell transplantation (data unavailable for eight studies). The overall risk of bias was high for all studies, in particular, due to incomplete follow‐up and the absence of blinding. None of the included studies had a control group so that no adequate comparative effect measures could be calculated. The duration of follow‐up varied substantially between studies, in particular, for harms. Our certainty in the evidence is very low for all outcomes. Overall survival was reported by eight studies (567 participants). Four studies reported survival rates at 12 months which ranged between 48% and 59%, and one study reported an overall survival rate of 50.5% at 24 months. The evidence is very uncertain about the effect of CAR T‐cell therapy on overall survival. Two studies including 294 participants at baseline and 59 participants at the longest follow‐up (12 months or 18 months) described improvements of quality of life measured with the EuroQol 5‐Dimension 5‐Level visual analogue scale (EQ‐5D‐5L VAS) or Function Assessment of Cancer Therapy‐Lymphoma (FACT‐Lym). The evidence is very uncertain about the effect of CAR T‐cell therapy on quality of life. None of the studies reported treatment‐related mortality. Five studies (550 participants) reported the occurrence of adverse events among participants, ranging between 99% and 100% for any grade adverse events and 68% to 98% for adverse events grade ≥ 3. In three studies (253 participants), 56% to 68% of participants experienced serious adverse events, while in one study (28 participants), no serious adverse events occurred. CAR T‐cell therapy may increase the risk of adverse events and serious adverse events but the evidence is very uncertain about the exact risk. The occurrence of cytokine release syndrome (CRS) was reported in 11 studies (675 participants) under use of various grading criteria. Five studies reported between 42% and 100% of participants experiencing CRS according to criteria described in Lee 2014. CAR T‐cell therapy may increase the risk of CRS but the evidence is very uncertain about the exact risk. Nine studies (575 participants) reported results on progression‐free survival, disease‐free survival or relapse‐free survival. Twelve‐month progression‐free survival rates were reported by four studies and ranged between 44% and 75%. In one study, relapse‐free survival remained at a rate of 64% at both 12 and 18 months. The evidence is very uncertain about the effect of CAR T‐cell therapy on progression‐free survival. Thirteen studies (620 participants) provided data on complete response rates. At six months, three studies reported complete response rates between 40% and 45%. The evidence is very uncertain about the effect of CAR T‐cell therapy on complete response rates. Authors' conclusions The available evidence on the benefits and harms of CAR T‐cell therapy for people with r/r DLBCL is limited, mainly because of the absence of comparative clinical trials. The results we present should be regarded in light of this limitation and conclusions should be drawn very carefully. Due to the uncertainty in the current evidence, a large number of ongoing investigations and a risk of substantial and potentially life‐threatening complications requiring supplementary treatment, it is critical to continue evaluating the evidence on this new therapy.
- Published
- 2021
5. Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma
- Author
-
Ernst, Moritz, additional, Oeser, Annika, additional, Besiroglu, Burcu, additional, Caro-Valenzuela, Julia, additional, Abd El Aziz, Mohamed, additional, Monsef, Ina, additional, Borchmann, Peter, additional, Estcourt, Lise J, additional, Skoetz, Nicole, additional, and Goldkuhle, Marius, additional
- Published
- 2021
- Full Text
- View/download PDF
6. First-line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta-analysis
- Author
-
Angela Aldin, Ina Monsef, Nicole Skoetz, Anne Adams, Tina Jakob, Philipp Dahm, Axel Heidenreich, and Marius Goldkuhle
- Subjects
Oncology ,medicine.medical_specialty ,First line therapy ,business.industry ,Renal cell carcinoma ,Internal medicine ,Meta-analysis ,medicine ,Pharmacology (medical) ,business ,medicine.disease - Published
- 2020
7. First-line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta-analysis
- Author
-
Goldkuhle, Marius, additional, Aldin, Angela, additional, Jakob, Tina, additional, Adams, Anne, additional, Monsef, Ina, additional, Heidenreich, Axel, additional, Dahm, Philipp, additional, and Skoetz, Nicole, additional
- Published
- 2020
- Full Text
- View/download PDF
8. Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma
- Author
-
Goldkuhle, M, Ernst, M, Estcourt, LJ, Borchmann, P, Monsef, I, and Skoetz, N
- Subjects
Medicine General & Introductory Medical Sciences ,hemic and lymphatic diseases ,Pharmacology (medical) - Abstract
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To assess the benefits, harms and costs of chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphomas (DLBCLs) in accordance with the available body of evidence.
- Published
- 2019
9. Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer)
- Author
-
Gerald Gartlehner, Maria Dimaki, Nicole Skoetz, Bastian von Tresckow, Marius Goldkuhle, Ina Monsef, Andreas Engert, Philipp Dahm, and Jan Peter Glossmann
- Subjects
Adult ,Medicine General & Introductory Medical Sciences ,medicine.medical_specialty ,Antineoplastic Agents ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,Randomized controlled trial ,Quality of life ,law ,Interquartile range ,Internal medicine ,Humans ,Medicine ,Pharmacology (medical) ,030212 general & internal medicine ,Brentuximab vedotin ,Adverse effect ,Response rate (survey) ,business.industry ,Antibodies, Monoclonal ,Hodgkin Disease ,Nivolumab ,030220 oncology & carcinogenesis ,Cohort ,business ,Software ,medicine.drug - Abstract
Background Hodgkin's lymphoma (HL) is a cancer of the lymphatic system, and involves the lymph nodes, spleen and other organs such as the liver, lung, bone or bone marrow, depending on the tumour stage. With cure rates of up to 90%, HL is one of the most curable cancers worldwide. Approximately 10% of people with HL will be refractory to initial treatment or will relapse; this is more common in people with advanced stage or bulky disease. Standard of care for these people is high-dose chemotherapy and autologous stem cell transplantation (ASCT), but only 55% of participants treated with high-dose chemotherapy and ASCT are free from treatment failure at three years, with an overall survival (OS) of about 80% at three years. Checkpoint inhibitors that target the interaction of the programmed death (PD)-1 immune checkpoint receptor, and its ligands PD-L1 and PD-L2, have shown remarkable activity in a wide range of malignancies. Nivolumab is an anti-(PD)-1 monoclonal antibody and currently approved by the US Food and Drug Administration (FDA) for the treatment of melanoma, non-small cell lung cancer, renal cell carcinoma and, since 2016, for classical Hodgkin's lymphoma (cHL) after treatment with ASCT and brentuximab vedotin. Objectives To assess the benefits and harms of nivolumab in adults with HL (irrespective of stage of disease). Search methods We searched CENTRAL, MEDLINE, Embase, International Pharmaceutical Abstracts, conference proceedings and six study registries from January 2000 to May 2018 for prospectively planned trials evaluating nivolumab. Selection criteria We included prospectively planned trials evaluating nivolumab in adults with HL. We excluded trials in which less than 80% of participants had HL, unless the trial authors provided the subgroup data for these participants in the publication or after we contacted the trial authors. Data collection and analysis Two review authors independently extracted data and assessed potential risk of bias. We used the software RobotReviewer to extract data and compared results with our findings. As we did not identify any randomised controlled trials (RCTs) or non-RCTs, we did not meta-analyse data. Main results Our search found 782 potentially relevant references. From these, we included three trials without a control group, with 283 participants. In addition, we identified 14 ongoing trials evaluating nivolumab, of which two are randomised. Risk of bias of the three included studies was moderate to high. All of the participants were in relapsed stage, most of them were heavily pretreated and had received at least two previous treatments, most of them had also undergone ASCT. As we did not identify any RCTs, we could not use the software RobotReviewer to assess risk of bias. The software identified correctly that one study was not an RCT and did not extract any trial data, but extracted characteristics of the other two studies (although also not RCTs) in a sufficient way. Two studies with 260 participants evaluated OS. After six months, OS was 100% in one study and median OS (the timepoint when only 50% of participants were alive) was not reached in the other trial after a median follow-up of 18 months (interquartile range (IQR) 15 to 22 months) (very low certainty evidence, due to observational trial design, heterogenous patient population in terms of pretreatments and various follow-up times (downgrading by 1 point)). In one study, one out of three cohorts reported quality of life. It was unclear whether there was an effect on quality of life as only a subset of participants filled out the follow-up questionnaire (very low certainty evidence). Three trials (283 participants) evaluated progression-free survival (PFS) (very low certainty evidence). Six-month PFS ranged between 60% and 86%, and median PFS ranged between 12 and 18 months. All three trials (283 participants) reported complete response rates, ranging from 12% to 29%, depending on inclusion criteria and participants' previous treatments (very low certainty evidence). One trial (243 participants) reported drug-related grade 3 or 4 adverse events (AEs) only after a median follow-up of 18 months (IQR 15 to 22 months); these were fatigue (23%), diarrhoea (15%), infusion reactions (14%) and rash (12%). The other two trials (40 participants) reported 23% to 52% grade 3 or 4 AEs after six months' follow-up (very low certainty evidence). Only one trial (243 participants) reported drug-related serious AEs; 2% of participants developed infusion reactions and 1% pneumonitis (very low certainty evidence). None of the studies reported treatment-related mortality. Authors' conclusions To date, data on OS, quality of life, PFS, response rate, or short- and long-term AEs are available from small uncontrolled trials only. The three trials included heavily pretreated participants, which had previously undergone regimens of BV or ASCT. For these participants, median OS was not reached after follow-up times of at least 16 months (more than 50% of participants with a limited life expectancy were alive at this timepoint). Only one cohort out of three only reported quality of life, with limited follow-up data so that meaningful conclusions were not possible. Serious adverse events occurred rarely. Currently, data are too sparse to make a clear statement on nivolumab for people with relapsed or refractory HL except for heavily pretreated people, which had previously undergone regimens of BV or ASCT. When interpreting these results, it is important to consider that proper RCTs should confirm these findings. As there are 14 ongoing trials evaluating nivolumab, of which two are RCTs, it is possible that an update of this review will be published in the near future and that this update will show different results to those reported here.
- Published
- 2018
10. Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer)
- Author
-
Goldkuhle, Marius, primary, Dimaki, Maria, additional, Gartlehner, Gerald, additional, Monsef, Ina, additional, Dahm, Philipp, additional, Glossmann, Jan-Peter, additional, Engert, Andreas, additional, von Tresckow, Bastian, additional, and Skoetz, Nicole, additional
- Published
- 2018
- Full Text
- View/download PDF
11. Nivolumab for adult individuals with Hodgkin lymphoma (an exemplar rapid review using RobotReviewer)
- Author
-
Skoetz, Nicole, primary, Goldkuhle, Marius, additional, Gartlehner, Gerald, additional, Monsef, Ina, additional, Dahm, Philipp, additional, Glossmann, Jan-Peter, additional, Engert, Andreas, additional, and von Tresckow, Bastian, additional
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.